FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3035660910> ?p ?o ?g. }

• W3035660910 abstract "Aim: The FreeStyle Libre (FSL) flash glucose monitoring device was made available on the UK National Health Services (NHS) drug tariff in 2017. This study aims to explore the UK real-world experience of FSL and the impact on glycaemic control, hypoglycaemia, diabetes-related distress and hospital admissions. Methods: Clinicians from 102 National Health Service hospitals in the United Kingdom submitted FSL user data, collected during routine clinical care, to a secure web-based tool. T-tests and Mann-Whitney-U tests were used to compare the baseline and follow-up HbA1c and other baseline demographic characteristics. Linear regression analysis was used to identify predictors of change in HbA1c following the use of FSL. Within-person variations of HbA1c calculated adj-HbA1c-SD=SD/sq. Root [n/(n−1)]. Results: Data were available for 10,370 (97% with type 1 diabetes) FSL users; age 38 (±18.7) years, 54% female, diabetes duration 16 (±49) years, and BMI of 25.2 (±16.5) kg/m2. The baseline HbA1c was 69.8 (±18.2) (8.5%), and after a mean follow-up of 7.6 (±23)months (n=3182) HbA1c reduced to 62.3 (±18.5) (7.9%) mmol/l (P&lt;0.0001)). HbA1c reduction was greater in those with initial HbA1c ≥69.5 (&gt;8.5%) mmol/mol, HbA1c reduced from 85.5mmol/mol (±16.07) (10%) to 73.1 mmol/mol (±15.8) (8.8%)) (P&lt;0.0001). The baseline Gold score (score for hypoglycaemic unawareness) was 2.7 (±1.8) and reduced to 2.4 (±1.7) (P&lt;0.0001) at follow-up. 53% of those with a Gold score of ≥4 at baseline, regained hypoglycaemic awareness at follow-up. FSL use was also associated with a reduction in diabetes distress (P&lt;0.0001). Use of FSL was associated with significantly reduced paramedic callouts and hospital admissions due to hypoglycaemia and to hyperglycaemia/Diabetic Ketoacidosis (DKA). Conclusion: We show that the use of FSL was associated with significantly improved glycaemic control and hypoglycaemia awareness, and a reduction in hospital admissions. Disclosure H. Deshmukh: None. E.G. Wilmot: Advisory Panel; Self; Abbott, Dexcom, Inc., Eli Lilly and Company, Insulet Corporation, Medtronic. Speaker’s Bureau; Self; Abbott, Eli Lilly and Company, Insulet Corporation, Novo Nordisk Inc., Sanofi. J. Patmore: None. C. Walton: Speaker’s Bureau; Spouse/Partner; Celgene, LEO Pharma, Novartis Pharmaceuticals Corporation. R. Herring: None. R.E. Ryder: Consultant; Self; GI Dynamics Inc. Other Relationship; Self; Novo Nordisk A/S. T. Sathyapalan: Research Support; Self; Amgen, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Novo Nordisk A/S. Other Relationship; Self; Ipsen Biopharmaceuticals." @default.
• W3035660910 created "2020-06-19" @default.
• W3035660910 creator A5002256303 @default.
• W3035660910 creator A5034745495 @default.
• W3035660910 creator A5062170233 @default.
• W3035660910 creator A5066210592 @default.
• W3035660910 creator A5071127270 @default.
• W3035660910 creator A5088604122 @default.
• W3035660910 creator A5067556170 @default.
• W3035660910 date "2020-06-01" @default.
• W3035660910 modified "2023-10-17" @default.
• W3035660910 title "873-P: Flash Glucose Monitoring: Effect on Glycaemic Control, Hypoglycaemia, Diabetes-Related Distress, and Resource Utilization: A Nationwide Study" @default.
• W3035660910 doi "https://doi.org/10.2337/db20-873-p" @default.
• W3035660910 hasPublicationYear "2020" @default.
• W3035660910 type Work @default.
• W3035660910 sameAs 3035660910 @default.
• W3035660910 citedByCount "0" @default.
• W3035660910 crossrefType "journal-article" @default.
• W3035660910 hasAuthorship W3035660910A5002256303 @default.
• W3035660910 hasAuthorship W3035660910A5034745495 @default.
• W3035660910 hasAuthorship W3035660910A5062170233 @default.
• W3035660910 hasAuthorship W3035660910A5066210592 @default.
• W3035660910 hasAuthorship W3035660910A5067556170 @default.
• W3035660910 hasAuthorship W3035660910A5071127270 @default.
• W3035660910 hasAuthorship W3035660910A5088604122 @default.
• W3035660910 hasConcept C126322002 @default.
• W3035660910 hasConcept C134018914 @default.
• W3035660910 hasConcept C139265228 @default.
• W3035660910 hasConcept C187212893 @default.
• W3035660910 hasConcept C2777180221 @default.
• W3035660910 hasConcept C2780668416 @default.
• W3035660910 hasConcept C555293320 @default.
• W3035660910 hasConcept C70410870 @default.
• W3035660910 hasConcept C71924100 @default.
• W3035660910 hasConceptScore W3035660910C126322002 @default.
• W3035660910 hasConceptScore W3035660910C134018914 @default.
• W3035660910 hasConceptScore W3035660910C139265228 @default.
• W3035660910 hasConceptScore W3035660910C187212893 @default.
• W3035660910 hasConceptScore W3035660910C2777180221 @default.
• W3035660910 hasConceptScore W3035660910C2780668416 @default.
• W3035660910 hasConceptScore W3035660910C555293320 @default.
• W3035660910 hasConceptScore W3035660910C70410870 @default.
• W3035660910 hasConceptScore W3035660910C71924100 @default.
• W3035660910 hasIssue "Supplement_1" @default.
• W3035660910 hasLocation W30356609101 @default.
• W3035660910 hasOpenAccess W3035660910 @default.
• W3035660910 hasPrimaryLocation W30356609101 @default.
• W3035660910 hasRelatedWork W1563850031 @default.
• W3035660910 hasRelatedWork W2015926965 @default.
• W3035660910 hasRelatedWork W2415759662 @default.
• W3035660910 hasRelatedWork W2734421957 @default.
• W3035660910 hasRelatedWork W2805857714 @default.
• W3035660910 hasRelatedWork W3031821553 @default.
• W3035660910 hasRelatedWork W3036934084 @default.
• W3035660910 hasRelatedWork W3152935002 @default.
• W3035660910 hasRelatedWork W4211225525 @default.
• W3035660910 hasRelatedWork W4322723668 @default.
• W3035660910 hasVolume "69" @default.
• W3035660910 isParatext "false" @default.
• W3035660910 isRetracted "false" @default.
• W3035660910 magId "3035660910" @default.
• W3035660910 workType "article" @default.